Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Gomella on Enzalutamide in Prostate Cancer

February 27th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Gomella Discusses Apalutamide Approval and Other Progress in Prostate Cancer

February 23rd 2018

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Dr. Slovin Discusses GnRH Antagonists Versus Agonists

February 23rd 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

CTCs Demonstrate Predictive Power in Prostate Cancer

February 21st 2018

Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

February 20th 2018

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Maintaining Bone Health During ADT for Prostate Cancer

February 20th 2018

The use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

February 20th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

February 17th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer

February 16th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

FDA Approves Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

February 15th 2018

The FDA has approved apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

February 14th 2018

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

Expert Discusses Docetaxel Versus Abiraterone in Hormone-Sensitive Prostate Cancer

February 14th 2018

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

Dr. Koontz Discusses LHRH in High-Risk Prostate Cancer

February 14th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Sequencing Questions Remain in Prostate Cancer Paradigm

February 13th 2018

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix, Leuprolide in Prostate Cancer

February 11th 2018

Dr. Gulley Discusses a Phase II Study of Olaparib and Durvalumab in mCRPC

February 10th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

SM-88 Delays Recurrence for Nonmetastatic Prostate Cancer

February 9th 2018

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

Olaparib/Durvalumab Combo Shows Promise in mCRPC

February 9th 2018

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC

February 9th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).